Common side-effects of BTK inhibitors (ibrutinib and acalabrutinib) in the treatment of CLL
Overview of new combinaton therapies in acute myeloid leukemia (AML)
Naval G. Daver
Can we afford to have CLL patients on a therapy for the rest of their lives?
John Gribben et al.
m7-FLIPI identifies patients with early disease progression of FL after therapy
Next-generation sequencing data on myeloproliferative neoplasms